Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by barsaxon Nov 18, 2019 1:37pm

154 Views

Post# 30365590

RE:RE:RE:RE:LOL, that was impressive

"Let's get the cognitive data out there and see what that brings. Tik Tok one more time...it better be good."

In addition to the CTAD cognitive data I think we should look to further clarification on FDA Breakthrough Drug application/designation. That would be another catalyst for the stock, that would also play into settling on agreeable financing / partnership terms. That CKD data for folks with a low GFR (< 60) seems to screem out for consideration.

Bullboard Posts

Cannara reports record growth and profitability in Q4 2023